Celia Ning

Thomas Dawson

Neerja Hajela

Eran Elinav

Denise Kelly

Professor Denise Kelly joined Seventure Partners, a European Leader in Venture Capital, in 2015 as an Investment Advisor to the Life Sciences Team and is focused specifically, on Human Microbiome investment opportunities, globally. Prior to joining Seventure, Denise was Head of her Research Lab at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies. She is the main inventor on numerous EU and USA patent applications and during her career has collaborated with pharmaceutical and healthcare companies on several translational projects.Denise holds a BSc and PhD from Queens University, Belfast and an Emeritus Professorship from the University of Aberdeen.

Regina Karim

Jennifer Fouquier

Ting Fan Leung

Wei-Kai Wu

Jun Terauchi

Keir Nicholas-Haizelden

Jeroen Raes

Niranjan Nagarajan

Dr. Nagarajan is Associate Director and Senior Group Leader in the Genome Institute of Singapore, and Associate Professor in the Department of Medicine and Department of Computer Science at the National University of Singapore. His research focuses on developing cutting edge genome analytic tools and using them to study the role of microbial communities in human health. His team conducts research at the interface of genetics, computer science and microbiology, in particular using a systems biology approach to understand host-microbiome-pathogen interactions in various disease conditions. Dr. Nagarajan received a B.A. in Computer Science and Mathematics from Ohio Wesleyan University in 2000, and a Ph.D. in Computer Science from Cornell University in 2006 (Advisor: Prof. Uri Keich). He did his postdoctoral work in the Center for Bioinformatics and Computational Biology at the University of Maryland working on problems in genome assembly and metagenomics (Advisor: Prof. Mihai Pop).

Sang Sun Yoon

Alexander Aksenov

Dr. Aksenov earned his Ph.D. in Chemistry from the University of Florida in 2006. He completed postdoctoral training in mass spectrometry at the Carnegie Mellon University. After an additional year as a Senior Research Scientist at the Laboratory of Government Chemist in United Kingdom, he moved to University of California Davis in 2010, to join Mechanical and Aerospace DepartmentBioinstrumentation andBioMEMS laboratory as an Associate Specialist and then a Project Scientist the University of California San Diego. In 2021, he joined the Department of Chemistry at the University of Connecticut as an Assistant Professor. His expertise is inbioanalytical chemistry and mass spectrometry. His primary research activities and interests are in metabolomics, various aspects of basic and appliedbioanalytical chemistry andbiological research with topics mainly focusing onbiomarker discovery and chemical aspects ofbiological processes.

Ang Qi Yan

James Morton

Sunny Wong

Ratha-Korn Vilaichone

Eric Chun-Ming Huang

Professor Eric Huang’s research with 128 peer-reviewed research articles has been focused on therapeutic microbiome where microbes are used for development of vaccines, probiotics and other therapeutics.

Christophe Lay

Albert Dashi

Dr Albert Dashi (Chief Scientific Officer) is Sequential’s co-founder. He completed his PhD in molecular genetics, epigenetics and stem cell research at the National University of Singapore (NUS) and the Genome Institute of Singapore in 2019. In 2014, he received the Singapore International Graduate Award from A*STAR for his PhD research and was also awarded the “Young Investigator” award. He also won the “Young Entrepreneur Scheme” award by P&G for his innovative and business driven ideas. Prior moving to Singapore for his doctorate program, Albert obtained his Masters in Biomedical Sciences at University of Bern, Switzerland. With an MSc Biomedical Sciences and >10 published papers on molecular genetics, epigenetics and stem cell research

Joseph Sung

Arielle Ngin Wan Ning

Ping Hu

Ping Hu is the computational biology capability leader, R&D Director, and Principal Scientist of the Procter & Gamble Company Corporate Function Discovery & Innovation Platform. Ping has worked on various microbial-related projects covering industrial microbial contamination detection, probiotic product development, metagenomics, and meta-transcriptomics understanding of skin, scalp, oral, baby, feminine, fabric, and built environment microbial communities. Ping has experience in human clinical, genetics, and expressional data analysis, developing artificial intelligence-enabled bio-digital applications and database systems. Ping is also leading an effort to explore the new sequencing-based capability and its usage in microbial detection, quality control, and risk assessment evaluating technologies from Nanopore, PacBio, etc. Ping graduated from New York University Medical School with a Ph.D. in Basic Medical Sciences and from Washington University in St. Louis with a Master’s degree in Computer Sciences. You can access Ping’s publications and patents from the Google Scholar link below: https://scholar.google.gr/citations?user=hu7JOt4AAAAJ&hl=en

Tai L Guo

Antonio LC Gomes

Irma Bernadette S. Sitohang

Aarthi Ravikrishnan

Margaret J. Morris

Cristiano Sabelli

Jonathan Lee

Gan Renyou

Elvina Parlindungan

Patricia Conway

Dr Patricia Conway, BSc & MSc (Uni of Qld, Australia), PhD (UNSW Australia), is Visiting Prof at SCELSE at Nanyang Technological University, Singapore, Adjunct Prof at UNSW Australia and Chief Scientist/CEO and Founder of PC Biome Pte Ltd, Singapore. She is also Founder/Director and Research Director of two Biotech companies in Australia. She has successfully combined basic research and translational applications for over 30 years by being affiliated with university for supervision of doctoral students (>20 to date) and the basic research while being industry employed, or by working closely with industry while being university employed. She has over 100 publications in international peer reviewed journal. Several globally marketed products for gut microbiome modulation have been commercialised from her work, and are supported by the IP platform including over 20 primary patents.

Patricia’s research interests are gastrointestinal microbiology, probiotics and prebiotics, with particular emphasis on the importance of the gut microbiome for health and well-being. She has focused on mechanisms of bacterial adhesion, pathogen inhibition and immune modulation in animals and humans. In particular, health conditions linked to inflammation, infection and metabolic disorders and developing intervention strategies for improving health, especially in infants and the elderly.

Amy Lin

Martin Pagac

Kyle Young

Tarun Chopra

Adrien Nivoliez

Dr. Adrien NIVOLIEZ (PhD) serves as the Chief Executive Officer of biose® industrie, a leading Contract Development & Manufacturing Organization specializing in GMP pharmaceuticals for Live Biotherapeutic Products.

Driven by a passion for microbiome and microbiota sciences, biose® industrie offers a wide range of services, including:
• Product development encompassing fermentation, drying processes, and customized drug product solutions (such as capsules and tablets).
• Analytical development to meet international requirements (USP, PE, ICH, etc.).
• GMP Scale-up Platform for clinical batch production.
• GMP Industrial Platform for large-scale manufacturing, capable of handling volumes up to 5,000 liters.
• Expertise in global quality and regulatory affairs.

Arno Bouwens

Arno Bouwens is head of R&D at Perseus Biomics, where he leads the development of DynaMAP technology and platforms. With a background in engineering, Arno’s expertise lies in optical and electronic systems development. He earned his PhD from the École Polytechnique Fédérale de Lausanne in Switzerland, where he specialized in cutting-edge biomedical imaging technology. As a researcher, Arno worked on DNA mapping technology, and optical implementations of machine learning techniques. As an engineer, he worked on optical metrology instruments and satellite-based imaging hardware. He draws upon his experience to spearhead the development of groundbreaking technologies. His focus is on crafting precise and high-capacity data generation tools tailored specifically for applications in the life sciences.

Johnson Li

Cheri Chu

Dr. Cheri Chu is currently an Associate Director of R&D and Microbiome Science Leader at Unilever. Since joining the company in 2012, Dr. Chu has held roles across R&D hubs in China and the U.S., leading projects focused on fundamental microbiome research for skin and scalp. She drives scientific strategy and global innovation in microbiome science, translating research into impactful consumer products.
Dr. Chu holds a B.S. in Life Sciences from National Taiwan University, an M.S. in Immunology from Imperial College London School of Medicine, and a Ph.D. in Immunology from King’s College London School of Medicine.

Jie Tang

Fresthel Monica M. Climacosa

Blanca Perez-Sepulveda

Mengke Zhang